Related Experiment Video

Updated: Jul 5, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Molecular targeting agents in renal cell carcinoma: present strategies and future perspectives

Snezana K Bjelogrlic1, Sinisa Radulovic, Nada Babovic

  • 1Institute for Oncology and Radiology of Serbia, Pasterova 14, 11 000 Belgrade, Serbia. zanab@bitsyu.net

Current Pharmaceutical Design
|May 14, 2008
PubMed

Insights

Metastatic renal cell carcinoma (RCC) treatment is advancing with new molecularly targeted therapies. Understanding RCC molecular pathology offers new hope for patients resistant to traditional treatments.

Area of Science:

  • Oncology
  • Molecular Pathology
  • Translational Medicine

Background:

  • Metastatic renal cell carcinoma (RCC) exhibits resistance to conventional chemotherapy and radiotherapy.
  • Current immunotherapies benefit only a limited proportion of patients with advanced RCC.
  • Recent progress in understanding RCC molecular pathology has paved the way for novel therapeutic strategies.

Purpose of the Study:

  • To review the current understanding of RCC molecular pathology.
  • To discuss recent clinical data on targeted therapies for RCC.
  • To explore future directions in the development of targeted treatments for RCC.

Main Methods:

  • Literature review of molecular pathology in RCC.
  • Analysis of recent clinical trial data for targeted agents.
  • Discussion of ongoing and future research in RCC targeted therapy.

Main Results:

  • Significant advances in understanding RCC molecular drivers.
  • Emergence of molecularly targeted agents (small molecules, monoclonal antibodies) showing promise.
  • Several targeted therapies have reached advanced clinical development and regulatory approval.

Conclusions:

  • Molecularly targeted agents represent a significant advancement in RCC treatment.
  • Personalized treatment strategies based on molecular profiles are becoming increasingly important.
  • Continued research into RCC molecular pathology is crucial for developing more effective therapies.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...